EcoDrugPlus

Tumor Protein P53

Ensembl ID : ENSACLG00000004533
Gene Symbol: TP53
3 Cross references
231 Possible Orthologues:

Type-2 Angiotensin Ii Receptor-Like

Ensembl ID : ENSACLG00000024172
Gene Symbol: LOC113034006
3 Cross references
189 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSACLG00000000404
Gene Symbol: TYR
4 Cross references
196 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSACLG00000023639
Gene Symbol: TYR
3 Cross references
203 Possible Orthologues:

Tyrosine Hydroxylase

Ensembl ID : ENSACLG00000002667
Gene Symbol: TH
1 Cross references
188 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSACLG00000018592
Gene Symbol: TYK2
3 Cross references
196 Possible Orthologues:

Tyrosine Kinase With Immunoglobulin Like And Egf Like Domains 1

Ensembl ID : ENSACLG00000000607
Gene Symbol: TIE1
3 Cross references
207 Possible Orthologues:

Tyrosine-Protein Kinase Jak2-Like

Ensembl ID : ENSACLG00000023172
Gene Symbol: LOC113025906
3 Cross references
198 Possible Orthologues:

Tyrosine-Protein Kinase Jak2-Like

Ensembl ID : ENSACLG00000019560
Gene Symbol: LOC113033249
3 Cross references
194 Possible Orthologues:

Tyrosine-Protein Kinase Lyn-Like

Ensembl ID : ENSACLG00000021631
Gene Symbol: LOC113011048
3 Cross references
196 Possible Orthologues:

Tyrosine-Protein Kinase Fyna

Ensembl ID : ENSACLG00000011671
Gene Symbol: LOC113012164
3 Cross references
192 Possible Orthologues:

Tyrosine-Protein Kinase Yes

Ensembl ID : ENSACLG00000013282
Gene Symbol: LOC113009995
3 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).